METHODS: A retrospective historical cohort study was conducted at gynecologic oncology unit, Bhumibol Adulyadej Hospital, Royal Thai Air Force, Thailand. Data was collected from medical records of CIN cases from year 2016 to 2021. Inclusion criteria were subjects who were diagnosed of CIN and underwent LEEP with pathologic confirmation and followed up for two years (at 6 months, 1 year, and 2 years). Preoperative complete blood count (CBC) was obtained within one month for calculation as systemic inflammatory values.
RESULTS: One hundred and ten cases of CIN were enrolled. Mean age of participants was 48.1 years old. Three-fourths (83/110) of the participants had histological confirmation as CIN2/3. Sixteen (18/110) and twenty (22/110) percentage of cases had recurrence of disease at 1 and 2 years, respectively. Monocytes /lymphocytes ratio (MLR) and systemic inflammation response index (SIRI) could predict recurrence of CIN within 2 years. MLR more than 0.16 and SIRI more than 0.57 gave the sensitivity and negative predictive value (NPV) at percentage of 77.3/ 81.8 and 91.8/ 90.2, respectively. Combination of MLR and SIRI had sensitivity and NPV at 90.5 and 95.4 percent, respectively. MLR and SIRI could not predict marginal involvement, glandular involvement, and LEEP confirmed CIN 2/3.
CONCLUSIONS: Pretreatment MLR and SIRI were statistically significant in predicting the recurrence in CIN after post LEEP procedure within 2 years follow up.
方法:在妇科肿瘤病房进行了一项回顾性历史队列研究,普密蓬阿杜德医院,泰国皇家空军,泰国。数据来自2016年至2021年CIN病例的医疗记录。纳入标准是被诊断为CIN并接受LEEP并经病理证实并随访两年的受试者(在6个月时,1年,和2年)。在一个月内获得术前全血细胞计数(CBC),以计算为全身炎症值。
结果:纳入110例CIN。参与者的平均年龄为48.1岁。四分之三(83/110)的参与者有组织学确认为N2/3。16(18/110)和20(22/110)百分比的病例在1年和2年复发,分别。单核细胞/淋巴细胞比率(MLR)和全身炎症反应指数(SIRI)可以预测CIN在2年内的复发。MLR大于0.16和SIRI大于0.57给出的灵敏度和阴性预测值(NPV)的百分比分别为77.3/81.8和91.8/90.2。MLR和SIRI组合的敏感性和NPV分别为90.5%和95.4%,分别。MLR和SIRI无法预测边际参与,腺体受累,和LEEP确认CIN2/3。
结论:治疗前MLR和SIRI在预测LEEP术后2年内CIN复发方面具有统计学意义。